The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1100
March 19, 2001
View Complete Issue         Table of Contents 2019 
Once-a-week Alendronate (Fosamax)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Once-a-week Alendronate (Fosamax)
March 19, 2001 (Issue: 1100)
Once-a-week formulations of alendronate (Fosamax) in 35- and 70-mg tablets have now been approved by the FDA and are being heavily promoted for prevention and treatment of postmenopausal osteoporosis. A new formulation of risedronate (Actonel) for...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Once-a-week Alendronate (Fosamax)
Article code: 1100c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.